Cytosorbents Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $37.2M+4.5% YoYTTM through 31 Mar 2026
Net Income -$18.2MTTM through 30 Jun 2026
Free Cash Flow -$9.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 71.0% |
| EBITDA Margin | -30.9% |
| Operating Margin | -39.6% |
| Net Margin | -49.0% |
Returns
-138.9%ROE
-18.6%ROA
Balance Sheet Health
Debt / Equity2.82x
Current Ratio2.13x
Net Debt$10.4M
Cash & Equivalents$4.4M
Quality Metrics
Altman Z-Score-12.01
Piotroski F-Score6 / 9
FCF Margin-25.0%
Rule of 40-20.5
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $37.1M
Diluted EPS-$0.29TTMFY2025: $-0.13
Dividend
No dividend
Capital Allocation
Capex Intensity0.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Direct Sales Outside Germany | $8.6M | +13.0% | View detailsHealthy growth driven by expanding clinical adoption and brand momentum. |
| Distributor Sales | $16.5M | +11.4% | View detailsStrong performance led by record distributor territory sales. |
| Germany Direct Sales | $11.8M | -10.0% | View detailsReflects near-term impact of proactive sales team restructuring; operational improvements expected to drive scalable growth. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.